首页> 外文期刊>Pharmacology Research & Perspectives >Comparison between esomeprazole 20 mg Vs 40 mg as stress ulcer prophylaxis (SUP) in critically ill patients: A retrospective cohort study
【24h】

Comparison between esomeprazole 20 mg Vs 40 mg as stress ulcer prophylaxis (SUP) in critically ill patients: A retrospective cohort study

机译:Esomeprazole 20mg与40 mg之间的比较作为应激性溃疡预防患者的应激溃疡预防(Sup):回顾性队列研究

获取原文
           

摘要

Critically ill patients admitted to intensive care units (ICUs) are at high risk of developing upper gastrointestinal bleeding due to GI stress ulceration (SU). The major independent risk factors for the development of GI bleeding in the ICUs include mechanical ventilation (MV) and coagulopathy. There is no enough evidence regarding the most appropriate dosing of esomeprazole as stress ulcer prophylaxis (SUP) in critically ill patients. This is a retrospective cohort study conducted at King Abdulaziz Medical City-Riyadh between January and December 2018 to determine the efficacy and safety of two different regimens of esomeprazole (20 vs 40 mg) as SUP in critically ill patients with major risk factors of GI stress ulceration. A total of 1864 patients were reviewed, 387 patients meeting inclusion criteria were enrolled. The propensity score was used to adjust for clinically and statistically relevant variables. We considered a P value of .05 as statistically significant. 49 patients (12.6%) had received Esomeprazole 20?mg during the study period. Compared with Esomeprazole 20?mg, Esomeprazole 40?mg was not superior in GI bleeding prevention (aOR 2.611, 95% CI 0.343-20.247, P?=?.356). In addition, neither ICU C. difficle, ICU mortality within 30?days, ICU LOS, hospital LOS, ICU re-admission within 6?months, RBCs transfusion, nor platelets transfusion requirements were significant. On the other hand, Esomeprazole 40?mg was statistically associated with Enterobacteriaceae, Pneumonia, and longer MV duration.? 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
机译:患有重症监护单位(ICU)的患者患者患有高风险,患GI应力溃疡(SU)引起上胃肠道出血。 ICU中GI出血的发展的主要独立风险因素包括机械通风(MV)和凝血病。没有足够的证据证明最适当的eSomeprazole作为重症患者的压力溃疡预防(Sup)。这是在2018年1月至12月在2018年1月至12月期间在Abdulaziz Medical City-Riyadh进行的回顾性队列研究,以确定两种不同的eSomeprazole方案(20 vs 40 mg)的疗效和安全,因为患有Gi压力的主要危险因素的危重患者溃疡。综述了1864名患者,招收了387名符合纳入标准的患者。倾向评分用于调整临床和统计相关的变量。我们认为p值<.05,如统计上显着。 49名患者(12.6%)在研究期间接受了eSomeprazole 20?MG。与eSomeprazole 20?mg相比,eSomeprazole 40?mg在gi出血预防下不优于(aor 2.611,95%ci 0.343-20.247,p?= 356)。此外,ICU C. Difficle既不在30?天内,ICU LOS,Hospital LOS,ICU在6?几个月内重新入场,RBC输血或血小板输血要求都是显着的。另一方面,eSomeprazole 40?Mg与肠杆菌,肺炎和更长的MV持续时间有统计学相关。 2020作者。 John Wiley&Sons Ltd,英国药理学会和美国药理学学会和实验治疗学士发表的药理学研究与观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号